Live feed03:00:00·8mPRReleasevia QuantisnowU.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment ExpectationsByQuantisnow·Wall Street's wire, on your screen.TAK· Takeda Pharmaceutical Company LimitedHealth Care
